# Therapeutic Hypotheses: Chaperone Selectivity for Pathological Conformers
## Hypothesis 1: Co-chaperone heterogeneity determines conformational discrimination
**Title:** J-protein co-chaperone repertoire enables selective recognition of pathogenic conformers
**Mechanism:** DNAJB6 (HSP40 family) exhibits selective anti-amyloid activity distinct from DNAJB2, which favors protein refolding. The differential interaction kinetics between specific J-proteins and HSP70 create a "client code" that preferentially engages with the structured β-sheetrich cores of pathological aggregates versus the more helical, solvent-exposed intermediates in normal folding trajectories.
**Target:** DNAJB6/DNAJB2 ratio; HSP70 (HSPA8/HSPA1A) client complexes
**Supporting Evidence:**
- DNAJB6 specifically suppresses polyglutamine aggregation (PMID: 17993627)
- DNAJB2 selectively disaggregates stress granules (PMID: 34541823)
- HSF1 activation increases anti-aggregation J-protein expression (PMID: 28017844)
**Predicted Experiment:** CRISPRi screens targeting 50+ J-protein family members in iPSC-derived neurons with α-synuclein PFF seeding; measure pathologic inclusions vs. cell viability to map selectivity landscape.
**Confidence:** 0.65
---
## Hypothesis 2: Phosphorylation-dependent allosteric remodeling of HSP90 client selectivity
**Title:** CK2-mediated HSP90α phosphorylation switches client discrimination toward disease conformers
**Mechanism:** Casein kinase 2 (CK2) phosphorylates HSP90α at T115 and S226, allosterically remodeling the ATP-binding pocket and N-terminal domain interface. This post-translational modification increases affinity for hyperphosphorylated tau conformers while reducing association with nascent folding intermediates. CK2 inhibitors (CX-4945) would restore broader client selectivity at the cost of reduced engagement with pathologic conformers.
**Target:** CK2-HSP90α axis; phosphorylation-dependent client recognition
**Supporting Evidence:**
- CK2 phosphorylates tau at multiple AD-relevant sites (PMID: 29374255)
- HSP90 inhibitors show disease-modifying effects in tauopathy models (PMID: 30258079)
- N-terminal HSP90 phosphorylation correlates with neurodegeneration (PMID: 33741461)
**Predicted Experiment:** Isothermal titration calorimetry comparing phosphorylated vs. non-phosphorylated HSP90α binding to recombinant tau pre-formed fibrils vs. monomeric tau; validate with phospho-mimetic T115E/S226E mutants.
**Confidence:** 0.55
---
## Hypothesis 3: Metastable hydrophobic segment exposure as pathologic recognition motif
**Title:** Exposed amyloidogenic segments ( residues with high β-sheet propensity) serve as HSP70 recognition codes
**Mechanism:** Pathological conformers expose "aggregation nucleation" sequences—typically 5-15 residue hydrophobic stretches—that are buried in native folds. HSP70 binds these segments with higher affinity than their native counterparts due to chronic exposure in misfolded states. The thermodynamic preference for these segments explains apparent "selectivity" for pathogenic species over transient native-state fluctuations.
**Target:** HSPA8/HSPA1A substrate-binding domain; aggregation-prone sequences in TDP-43, α-synuclein, tau, huntingtin
**Supporting Evidence:**
- HSP70 preferentially binds α-synuclein at N-terminal and NAC regions (PMID: 29463785)
- J-domain proteins enhance HSP70 affinity for amyloid cores (PMID: 33902342)
- HSP70 suppresses early nucleation steps in aggregation kinetics (PMID: 33427873)
**Predicted Experiment:** Hydrogen-deuterium exchange mass spectrometry mapping HSP70 binding sites on α-synuclein monomer vs. PFF; compare wild-type to A53T mutant to quantify conformational selectivity.
**Confidence:** 0.70
---
## Hypothesis 4: E3 ligase triage decision as pathologic discriminator
**Title:** CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformers for proteasomal degradation
**Mechanism:** The co-chaperone CHIP (STUB1) bridges HSP70/HSP90 to the proteasome. Pathological oligomers uniquely engage HSP70 in a conformation that stabilizes the HSP70-CHIP interaction, directing ubiquitination. Monomeric or small oligomeric intermediates remain in the HSP70-CHIP "refolding zone" longer, allowing native-state recovery.
**Target:** CHIP (STUB1); HSP70-CHIP complex formation; K48-linked ubiquitination
**Supporting Evidence:**
- CHIP preferentially ubiquitinates misfolded over native proteins (PMID: 27212786)
- HSP70-CHIP complex degrades polyglutamine aggregates (PMID: 29995934)
- Loss of CHIP exacerbates tau pathology in vivo (PMID: 28642586)
**Predicted Experiment:** Co-immunoprecipitation of endogenous HSP70-CHIP complexes from HEK293T expressing GFP-tagged α-synuclein monomer vs. pre-formed fibrils; quantify complex stability and ubiquitination via immunoblot. Test with CHIP mutants defective in E3 ligase activity.
**Confidence:** 0.60
---
## Hypothesis 5: Membrane interfacial selectivity for lipid-anchored pathologic conformers
**Title:** Membrane curvature and lipid raft composition enable differential recognition of pathogenic α-synuclein conformers
**Mechanism:** α-synuclein exists in distinct membrane-bound conformations: α-helical (physiologic, on synaptic vesicles) vs. β-sheet-rich (pathologic, on disrupted membranes). HSP70 preferentially binds the helical conformation via